Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...

Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...

A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the ...

Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Elevidys, Sarepta’s gene therapy for DMD, has demonstrated significant commercial success since receiving expanded label approval for patients aged 6 and older. The therapy has exceeded revenue ...

After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...

Mizuho views the selloff in shares of Sarepta (SRPT) yesterday due to concerns about Elevidys adoption as a result of the fatal acute liver ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...